Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

To the Editor:

Omicron Subvariant Mutations and Neutralizing Antibody Responses.

Panel A reveals the lineage of mutations which were recognized within the omicron BA.1, BA.2, BA.2.12.1, and BA.4 or BA.5 subvariants of SARS-CoV-2, as in contrast with the reference WA1 / 2020 remoted. BA.4 and BA.5 have similar sequences of the spike protein and thus have been grouped collectively. FP denotes fusion peptide, HR1 heptad repeat 1, HR2 heptad repeat 2, NTD N-terminal area, RBD receptor-binding area, RBM receptor-binding motif, SD1 subdomain 1, and SD2 subdomain 2. Panel B reveals neutralizing antibody titers as decided by luciferase-based pseudovirus neutralization assays in samples obtained from 27 contributors 6 months after receipt of the two-dose BNT162b2 messenger RNA vaccine collection and a couple of weeks after the third (booster) dose. Panel C reveals neutralizing antibody titers in contributors who had been contaminated with the BA.1 or BA.2 subvariant. All of the contaminated contributors had been vaccinated apart from 1 participant who had a detrimental neutralizing antibody titer. In 9 contributors, two or three time factors after an infection are proven. Neutralizing antibody titers had been measured in opposition to the SARS-CoV-2 reference isolate WA1 / 2020 and the omicron BA.1, BA.2, BA.2.12.1, and BA.4 or BA.5 subvariants. In Panels B and C, medians (black bars) are proven numerically, and issue variations from different subvariants are indicated; the dashed horizontal line signifies the decrease restrict of detection for the assay.

In current months, a number of lineages of the omicron (B.1.1.529) variant of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged,1 with subvariants BA.1 and BA.2 exhibiting substantial escape from neutralizing antibodies.2-5 Subvariant BA.2.12.1 is now the dominant pressure in the USA, and BA.4 and BA.5 are dominant in South Africa (Determine 1A). Subvariants BA.4 and BA.5 have similar sequences of the spike protein.

We evaluated neutralizing antibody titers in opposition to the reference WA1 / 2020 isolate of SARS-CoV-2 together with omicron subvariants BA.1, BA.2, BA.2.12.1, and BA.4 or BA.5 in 27 contributors who had been vaccinated and boosted with messenger RNA vaccine BNT162b2 (Pfizer – BioNTech) and in 27 contributors who had been contaminated with the BA.1 or BA.2 subvariant a median of 29 days earlier (vary, 2 to 113) (Tables S1 and S2 within the Supplementary Appendix, obtainable with the complete textual content of this letter at NEJM.org). Within the vaccine cohort, contributors had been excluded if that they had a historical past of SARS-CoV-2 an infection or a optimistic end result on nucleocapsid serologic evaluation or if that they had acquired one other vaccine in opposition to coronavirus illness 2019 (Covid-19) or an immunosuppressive medicine.

Six months after the preliminary two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 in opposition to WA1 / 2020 however lower than 20 in opposition to all of the examined omicron subvariants (Determine 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer elevated considerably, to 5783 in opposition to the WA1 / 2020 isolate, 900 in opposition to the BA.1 subvariant, 829 in opposition to the BA.2 subvariant, 410 in opposition to the BA.2.12.1 subvariant, and 275 in opposition to the BA.4 or BA.5 subvariant. These information present that as in contrast with the response in opposition to the WA1 / 2020 isolate, the neutralizing antibody titer was decrease by an element of 6.4 in opposition to BA.1, by an element of seven.0 in opposition to BA.2, by an element of 14.1 in opposition to BA. 2.12.1, and by an element of 21.0 in opposition to BA.4 or BA.5. As well as, as in contrast with the median neutralizing antibody titer in opposition to the BA.1 subvariant, the median titer was decrease by an element of two.2 in opposition to the BA.2.12.1 subvariant and by an element of three.3 in opposition to the BA.4 or BA. 5 subvariant.

Among the many contributors who had been contaminated with the BA.1 or BA.2 subvariant of omicron, all however one had been vaccinated in opposition to Covid-19. Due to the variation in sampling after the onset of an infection, some samples might not replicate peak neutralizing antibody titers (Desk S2). Among the many contributors with a historical past of Covid-19, the median neutralizing antibody titer was 11,050 in opposition to the WA1 / 2020 isolate, 1740 in opposition to the BA.1 subvariant, 1910 in opposition to the BA.2 subvariant, 1150 in opposition to the BA.2.12.1 subvariant , and 590 in opposition to the BA.4 or BA.5 subvariant (Determine 1C). These information present that as in comparison with the WA1 / 2020 isolate, the median neutralizing antibody titer was decrease by an element of 6.4 in opposition to BA.1, by an element of 5.8 in opposition to BA.2, by an element of 9.6 in opposition to BA.2.12. 1, and by an element of 18.7 in opposition to BA.4 or BA.5. As well as, as in comparison with the median titers in opposition to the BA.1 subvariant, the median titer was decrease by an element of 1.5 in opposition to the BA.2.12.1 subvariant and by an element of two.9 in opposition to the BA.4 or BA.5 subvariant .

These information present that the BA.2.12.1, BA.4, and BA.5 subvariants considerably escape neutralizing antibodies induced by each vaccination and an infection. Furthermore, neutralizing antibody titers in opposition to the BA.4 or BA.5 subvariant and (to a lesser extent) in opposition to the BA.2.12.1 subvariant had been decrease than titers in opposition to the BA.1 and BA.2 subvariants, which means that the SARS -CoV-2 omicron variant has continued to evolve with rising neutralization escape. These findings present immunologic context for the present surges attributable to the BA.2.12.1, BA.4, and BA.5 subvariants in populations with excessive frequencies of vaccination and BA.1 or BA.2 an infection.

Nicole P. Hachmann, BS
Jessica Miller, BS
Ai-ris Y. Collier, MD
John D. Ventura, Ph.D.
Jingyou Yu, Ph.D.
Marjorie Rowe, BS
Esther A. Bondzie, MSN
Olivia Powers, BS
Nehalee Surve, MS
Kevin Corridor, BS
Dan H. Barouch, MD, Ph.D.
Beth Israel Deaconess Medical Middle, Boston, MA
[email protected]

Supported by a grant (CA260476) from the Nationwide Institutes of Well being (NIH), by the Massachusetts Consortium for Pathogen Readinessand by the Ragon Institute. Dr. Barouch is supported by the Musk Basis. Dr. Collier is supported by the Reproductive Scientist Growth Program of the Eunice Kennedy Shriver Nationwide Institute of Youngster Well being and Human Growthby a grant (HD000849) from the Burroughs Wellcome Fund, and by a grant (AI69309) from the NIH.

Disclosure varieties supplied by the authors can be found with the complete textual content of this letter at NEJM.org.

This letter was revealed on June 22, 2022, at NEJM.org.

  1. 1. Viana R, Moyo S, Amoako DG, et al. Fast epidemic enlargement of the SARS-CoV-2 omicron variant in southern Africa. Nature 2022603:679686.

  2. 2. The S, Jackson L, Khoury DS, et al. Omicron extensively however incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022602:654656.

  3. 3. Liu L, Iketani S, Guo Y, et al. Putting antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 2022602:676681.

  4. 4. Yu J, Necklace AY, Rowe M, et al. Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. N Engl J Med 2022386:15791580.

  5. 5. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature 2022604:553556.

Leave a Comment

%d bloggers like this: